Dendritic cells and their role in tumor immunosurveillance

Innate Immunity

Volumn 19, Issue 1, 2013, Pages 98-111

  Strioga, Marius ^a   Schijns, Virgil ^b,c   Powell, Daniel J ^d   Pasukoniene, Vita ^a   Dobrovolskiene, Neringa ^a,e   Michalek, Jaroslav ^f,g  

^a VILNIUS UNIVERSITY   (Lithuania)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c Epitopoietics Research Corporation (ERC)   (Belgium)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e State Research Institute Center for Innovative Medicine   (Lithuania)

^f MASARYK UNIVERSITY   (Czech Republic)

^g Cellthera Ltd   (Czech Republic)

Author keywords

Dendritic cell biology; immunogenic and tolerogenic dendritic cells; immunosuppression; killer dendritic cells; tumor immunosurveillance; vascular leukocytes

Indexed keywords

B7 ANTIGEN; BORTEZOMIB; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD137 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CYTOKINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OX40 LIGAND; OXALIPLATIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOTHELIUM CELL; GAMMA RADIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; KILLER CELL; KILLER DENDRITIC CELL; MYELOID DENDRITIC CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHOTODYNAMIC THERAPY; PLASMACYTOID DENDRITIC CELL; REGULATORY DENDRITIC CELL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ULTRAVIOLET C RADIATION;

ANIMALS; CELL COMMUNICATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; MONITORING, IMMUNOLOGIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84872367173     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912449549     Document Type: Review

References (168)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011 ; 29: 235-271
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011 ; 331: 1565-1570
3. Shankaran V, Ikeda H, Bruce AT, et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 ; 410: 1107-1111
4. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005 ; 102: 18538-18543
5. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011 ; 71: 1263-1271
6. Galon J, Pages F, Marincola F, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 ; 10: 1-1
7. Bernard A, Lamy L, Alberti I. The two-signal model of T-cell activation after 30 years. Transplantation. 2002 ; 73: S31 - S35
8. Boesteanu AC, Katsikis PD. Memory T-cells need CD28 costimulation to remember. Semin Immunol. 2009 ; 21: 69-77
9. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SM. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med. 2011 ; 17: 65-77
10. Gimmi CD, Freeman GJ, Gribben JG, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA. 1993 ; 90: 6586-6590
11. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8+ T cells undergoing peripheral deletion in response to cross-presentation of self- antigen. J Exp Med. 2001 ; 194: 707-717
12. Chappert P, Schwartz RH. Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr Opin Immunol. 2010 ; 22: 552-559
13. Hoyne GF. Mechanisms that regulate peripheral immune responses to control organ-specific autoimmunity. Clin Dev Immunol. 2011 ; 2011: 294968-294968
14. Redmond WL, Marincek BC, Sherman LA. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol. 2005 ; 174: 2046-2053
15. Sirinivasan M, Frauwirth KA. Peripheral tolerance in CD8+ T cells. Cytokine. 2009 ; 46: 147-159
16. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005 ; 6: 1219-1227
17. Levings MK, Gregori S, Tresoldi E, et al. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105: 1162-1169.
18. Nussenzweig MC, Steinman RM, Gutchinov B, Cohn ZA. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med. 1980 ; 152: 1070-1084
19. Stagg AJ, Knight SC Antigen-presenting Cells. Chichester: eLS John Wiley & Sons Ltd ; 2001 :
20. Fürnrohr BG, Sheriff A, Munoz L, et al. Signals, receptors, and cytokines involved in the immunomodulatory and anti-inflammatory properties of apoptotic cells. Signal Transduct. 2005 ; 5: 356-365
21. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology. 2008 ; 123: 326-338
22. Kaliński P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999 ; 20: 561-567
23. Ma CS, Tangye SG, Deenick EK. Human Th9 cells: inflammatory cytokines modulate IL-9 production through the induction of IL-21. Immunol Cell Biol. 2010 ; 88: 621-623
24. Amsen D, Blander JM, Lee GR, et al. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen -presenting cells. Cell. 2004 ; 117: 515-526
25. Curtsinger JM, Lins DC, Johnson CM, Mescher MF. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol. 2005 ; 175: 4392-4399
26. Kratky W, Reis e Sousa C, Oxenius A, Spörri R. Direct activation of antigen -presenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc Natl Acad Sci USA. 2011 ; 108: 17414-17419
27. Watchmaker PB, Berk E, Muthuswamy R, et al. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol. 2010 ; 184: 591-597
28. Macagno A, Napolitani G, Lanzavecchia A, Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol. 2007 ; 28: 227-233
29. Spörri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T-cell populations lacking helper function. Nat Immunol. 2005 ; 6: 163-170
30. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. 2009 ; 227: 234-247
31. Chang CS, Chang JH, Hsu NC, et al. Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma. BMC Cancer. 2007 ; 7: 88-88
32. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001 ; 411: 1058-1064
33. Petersen TR, Dickgreber N, Hermans IF. Tumor antigen presentation by dendritic cells. Crit Rev Immunol. 2010 ; 30: 345-386
34. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007 ; 449: 419-426
35. Klechevsky E, Morita R, Liu MC, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008 ; 29: 497-510
36. Piccioli D, Tavarini S, Borgogni E, et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood. 2007 ; 109: 5371-5379
37. Satthaporn S, Eremin O. Dendritic cells (I): biological functions. J R Coll Surg Edinb. 2001 ; 46: 9-19
38. Giroux M, Schmidt M, Descoteaux A. IFN-γ-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-α. J Immunol. 2003 ; 171: 4187-4194
39. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003 ; 14: 265-273
40. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity. 2005 ; 23: 503-514
41. Choi J, Enis DR, Koh KP, et al. T lymphocyte-endothelial cell interactions. Annu Rev Immunol. 2004 ; 22: 683-709
42. Ueno H, Schmitt N, Klechevsky E, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010 ; 234: 199-212
43. Ueda Y, Hagihara M, Okamoto A, et al. Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. Hum Immunol. 2003 ; 64: 1144-1151
44. Masten BJ, Olson GK, Tarleton CA, et al. Characterization of myeloid and plasmacytoid dendritic cells in human lung. J Immunol. 2006 ; 177: 7784-7793
45. Osugi Y, Vuckovic S, Hart DNJ. Myeloid blood CD11c+ dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002 ; 100: 2858-2866
46. del Hoyo GM, Martin P, Vargas HH, et al. Characterization of a common precursor population for dendritic cells. Nature. 2002 ; 415: 1043-1047
47. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009 ; 324: 392-397
48. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010 ; 234: 45-54
49. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol. 2006 ; 18: 503-511
50. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity. 2006 ; 25: 153-162
51. Allenspach EJ, Lemos MP, Porrett PM, et al. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity. 2008 ; 29: 795-806
52. MacDonald KPA, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002 ; 100: 4512-4520
53. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010 ; 207: 1247-1260
54. Robbins SH, Walzer T, Dembele D, et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 2008 ; 9: R17 - R17
55. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010 ; 116: E74 - E80
56. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010 ; 33: 464-478
57. Cao W. Molecular characterization of human plasmacytoid dendritic cells. J Clin Immunol. 2009 ; 29: 257-264
58. Reizis B, Bunin A, Ghosh HS, et al. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol. 2011 ; 29: 163-183
59. Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol. 2009 ; 182: 6815-6823
60. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science. 2010 ; 330: 656-661
61. Swiecki M, Colonna M. Accumulation of plasmacytoid DC: roles in disease pathogenesis and targets for immunotherapy. Eur J Immunol. 2010 ; 40: 2094-2098
62. Pillarisetty VG, Shah AB, Miller G, et al. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004 ; 172: 1009-1017
63. Villadangos JA, Young L. Antigen -presentation properties of plasmacytoid dendritic cells. Immunity. 2008 ; 29: 352-361
64. Di Pucchio T, Chatterjee B, Smed-Sorensen A, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008 ; 9: 551-557
65. Young LJ, Wilson NS, Schnorrer P, et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen -presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol. 2008 ; 9: 1244-1252
66. Sozzani S, Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010 ; 31: 270-277
67. Liou LY, Blasius AL, Welch MJ, et al. In vivo conversion of BM plasmacytoid DC into CD11b+ conventional DC during virus infection. Eur J Immunol. 2008 ; 38: 3388-3394
68. Lindstedt M, Lundberg K, Borrebaeck CAK. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J Immunol. 2005 ; 175: 4839-4846
69. Kerkmann M, Rothenfusser S, Hornung V, et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type IIFN synthesis in human plasmacytoid dendritic cells. J Immunol. 2003 ; 170: 4465-4474
70. Wesa AK and Storkus WJ. Killer dendritic cells: mechanisms of action and therapeutic implications. Cell Death Differ 2008; 15: 51-57.
71. Giumont-Desrochers F, Boucher G, Dong Z, et al. Redefining interferon-producing killer dendritic cells as a novel intermediate in NK cell differentiation. Blood 2012; 119: 4349-4357.
72. Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007 ; 204: 1441-1451
73. Janjic BM, Lu GW, Pimenov A, et al. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol. 2002 ; 168: 1823-1830
74. Larmonier N, Fraszczak J, Lakomy D, et al. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother. 2010 ; 59: 1-11
75. Lakomy D, Janikashvili N, Fraszczak J, et al. Cytotoxic dendritic cells generated from cancer patients. J Immunol. 2011 ; 187: 2775-2782
76. Kalantari T, Kamali-Sarvestani E, Ciric B, et al. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res. 2011 ; 51: 153-160
77. Serbina NV, Salazar-Mather TP, Biron CA, et al. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 2003 ; 19: 59-70
78. Hemmerling J, Wegner-Kops J, von Stebut E, et al. Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivo. J Immunol. 2011 ; 187: 1142-1149
79. O'Keeffe M, Hochrein H, Vremec D, et al. Mouse plasmacytoid cells: Long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8+ dendritic cells only after microbial stimulus. J Exp Med. 2002 ; 196: 1307-1319
80. Waskow C, Liu K, Darrasse-Jeze G, et al. The receptor tyrosine kinase FIt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008 ; 9: 676-683
81. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009 ; 78: 857-902
82. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol. 2003 ; 170: 2302-2309
83. Zhang QJ, Li XL, Wang D, et al. Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T-cell responses. PLoS ONE. 2008 ; 3: e3097 - e3097
84. Yang CJ, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011 ; 2011: 842-849
85. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005 ;: 975-1028
86. Flinsenberg TWH, Compeer EB, Boelens JJ, Boes M. antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol. 2011 ; 165: 8-18
87. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011 ; 30: 16-34
88. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008 ; 8: 279-289
89. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007 ; 28: 429-436
90. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 2010 ; 22: 105-112
91. Munz C, Steinman RM, Fujii SI. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005 ; 202: 203-207
92. Benvenuti F, Lagaudriere-Gesbert C, Grandjean I, et al. Dendritic cell maturation controls adhesion, synapse formation, and the duration of the interactions with naive T lymphocytes. J Immunol. 2004 ; 172: 292-301
93. Guermonprez P, Valladeau J, Zitvogel L, et al. antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002 ; 20: 621-667
94. Prazma CM, Tedder TF. Dendritic cell CD83: A therapeutic target or innocent bystander?. Immunol Lett. 2008 ; 115: 1-8
95. Platt CD, Ma JK, Chalouni C, et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci USA. 2010 ; 107: 4287-4292
96. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998 ; 393: 474-478
97. Fujii SI, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004 ; 199: 1607-1618
98. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009 ; 229: 152-172
99. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005 ; 434: 88-93
100. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011 ; 241: 206-227
101. Steinman RM, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann NY Acad Sci. 2003 ;: 15-25
102. Krempski J, Karyampudi L, Behrens MD, et al. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 ; 186: 6905-6913
103. Manavalan JS, Rossi PC, Vlad G, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11: 245-258.
104. Azzaoui I, Yahia SA, Chang Y, et al. CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects. Blood. 2011 ; 118: 3549-3558
105. Kuang DM, Zhao Q, Xu J, et al. Tumor-educated tolerogenic dendritic cells induce CD3ε down-regulation and apoptosis of T-cells through oxygen-dependent pathways. J Immunol. 2008 ; 181: 3089-3098
106. Stoop JN, Harry RA, von Delwig A, et al. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 2010 ; 62: 3656-3665
107. Tjomsland V, Spangeus A, Sandstrom P, et al. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS ONE. 2010 ; 5: e13441 - e13441
108. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002 ; 23: 445-449
109. Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta. 2009 ; 1795: 16-24
110. Steinbrink K, Mahnke K, Grabbe S, et al. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?. Hum Immunol. 2009 ; 70: 289-293
111. Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 2010 ; 116: 935-944
112. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000 ; 18: 767-811
113. Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 ; 68: 889-892
114. van Gisbergen KPJM, Aarnoudse CA, Meijer GA, et al. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res. 2005 ; 65: 5935-5944
115. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008 ; 20: 504-511
116. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009 ; 9: 353-363
117. Griffith TS, Ferguson TA. Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells. Immunity. 2011 ; 35: 456-466
118. Geske FJ, Monks J, Lehman L, Fadok VA. The role of the macrophage in apoptosis: hunter, gatherer, and regulator. Int J Hematol. 2002 ; 76: 16-26
119. Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol. 2004 ; 173: 2985-2994
120. Rothlin CV, Ghosh S, Zuniga EI, et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007 ; 131: 1124-1136
121. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest. 1998 ; 101: 890-898
122. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 1997 ; 390: 350-351
123. Girkontaite I, Urbonaviciute V, Maseda D, et al. Apoptotic cells selectively suppress the Th1 cytokine interferon G in stimulated human peripheral blood mononuclear cells and shift the Th1/Th2 balance towards Th2. Autoimmunity. 2007 ; 40: 327-330
124. Chen WJ, Frank ME, Jin WW, Wahl SM. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity. 2001 ; 14: 715-725
125. Ma YT, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010 ; 22: 113-124
126. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010 ; 140: 798-804
127. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011 ; 8: 151-160
128. Hannani D, Sistigu A, Kepp O, et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 2011 ; 17: 351-358
129. Garrido G, Rabasa A, Sánchez B, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol. 2011 ; 187: 4954-4966
130. Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007 ; 109: 4839-4845
131. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci. 2011 ; 10: 670-680
132. Schwaab T, Weiss JE, Schned AR, Barth RJ. Dendritic cell infiltration in colon cancer. J Immunother. 2001 ; 24: 130-137
133. Iwamoto M, Shinohara H, Miyamoto A, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer. 2003 ; 104: 92-97
134. Daud AI, Mirza N, Lenox B, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008 ; 26: 3235-3241
135. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003 ; 33: 1052-1062
136. Stoitzner P, Green LK, Jung JY, et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother. 2008 ; 57: 1665-1673
137. Perrot I, Blanchard D, Freymond N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007 ; 178: 2763-2769
138. Dumitriu IE, Dunbar DR, Howie SE, et al. Human dendritic cells produce TGF-β1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2009 ; 182: 2795-2807
139. Norian LA, Rodriguez PC, O'Mara LA, et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009 ; 69: 3086-3094
140. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004 ; 172: 4100-4110
141. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 1997 ; 73: 309-316
142. Wei S, Kryczek I, Zou LH, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005 ; 65: 5020-5026
143. Dunn GP, Bruce AT, Sheehan KCF, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005 ; 6: 722-729
144. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003 ; 63: 6478-6487
145. Cai DQ, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009 ; 9: 102-102
146. Vermi W, Soncini M, Melocchi L, et al. Plasmacytoid dendritic cells and cancer. J Leukoc Biol. 2011 ; 90: 681-690
147. Chaput N, Conforti R, Viaud S, et al. The Janus face of dendritic cells in cancer. Oncogene. 2008 ; 27: 5920-5931
148. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007 ; 204: 1037-1047
149. Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006 ; 177: 3448-3460
150. Apetoh L, Végran F, Ladoire S, Ghirighelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med. 2011 ; 11: 365-372
151. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009 ; 86: 1065-1073
152. Pinzon-Charry A, Ho CSK, Maxwell T, et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 2007 ; 97: 1251-1259
153. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004 ; 64: 5535-5538
154. Fainaru O, Almog N, Yung CW, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 2010 ; 24: 1411-1418
155. Sprague L, Muccioli M, Pate M, et al. The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. BMC Immunol. 2011 ; 12: 35-35
156. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer. 2005 ; 92: 1182-1187
157. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004 ; 10: 950-958
158. Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. Vascular leukocytes contribute to tumor vascularization. Blood. 2005 ; 105: 679-681
159. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 2008 ; 68: 7684-7691
160. Nierkens S, Janssen EM. Harnessing dendritic cells for tumor antigen presentation. Cancers. 2011 ; 3: 2195-2213
161. Srinivasan R, Van Epps DE. Specific active immunotherapy of cancer: potential and perspectives. Rev Recent Clin Trials. 2006 ; 1: 283-292
162. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010 ; 2: 37-56
163. Viaud S, Thery C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res. 2010 ; 70: 1281-2185
164. Baxevanis CN, Perez SA, Papamichail M. Developing effective cancer vaccines. Eur J Cancer. 2011 ; 47: S364 - S365
165. Gustafsson K, Junevik K, Werlenius O, et al. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile. Scand J Immunol. 2011 ; 74: 318-326
166. Castiello L, Sabatino M, Jin P, et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother. 2011 ; 60: 457-466
167. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 ; 16: 399-403
168. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle. 2010 ; 9: 260-268